NovaRx Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel cell-based therapeutic vaccines for the treatment of cancer. The Company was founded by Dr Habib Fakhrai in 1997. Headquarters and manufacturing operations are in San Diego, California. The proprietary core technology upon which Lucanix® is based has been exclusively licensed to NovaRx on a worldwide basis. Lucanix® is a registered trademark of NovaRx Corporation.
Although the company's current clinical trials are for the treatment of advanced non-small cell lung cancer, the majority of other forms of cancer are expected to be susceptible to NovaRx's vaccine approach. One promising NovaRx pipeline therapy, Glionix™ for glioma, or brain cancer, has already been tested in a Phase 1 clinical trial.
|
